Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cellectar Biosciences: Q2 Earnings Insights

Cellectar Biosciences (NASDAQ:CLRB) reported its Q2 earnings results on Friday, August 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 5, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Cellectar Biosciences (NASDAQ:CLRB) reported its Q2 earnings results on Friday, August 5, 2022 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Cellectar Biosciences missed estimated earnings by 18.45%, reporting an EPS of $-1.22 versus an estimate of $-1.03.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0 which was followed by a 2.94% drop in the share price the next day.

To track all earnings releases for Cellectar Biosciences visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Industrial Supply Company W.W. Grainger Shares Are Higher After Reporting Q4 Earnings

By Lekha Gupta
February 2, 1:40 PM
W.W. Grainger's Q4 FY23 results beat expectations, reporting sales of $3.997 billion, a 5.1% YoY increase. Despite a slight miss on consensus, the company's adjusted EPS of $8.33 exceeded expectations. Grainger's upbeat performance, with an 11.5% YoY rise in adjusted operating profit, sets the stage for robust FY24 growth, projecting net sales between $17.2 billion and $17.7 billion, boosting GWW shares by 4.08% to $960.26.

GWW